Journal: Dialogues in Clinical Neuroscience

Article Title: Clinical translation of stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal cell biodelivery of glucagon-like peptide-1

doi:

Figure Lengend Snippet: Encapsulated mesenchymal cell biodelivery of GLP-1. Upper left: Human bone marrow-derived, mesenchymal stem cells producing GLP-1 are encapsulated with alginate (capsule diameter 500 to 600 urn, each capsule containing 3200 cells). As the capsules permit the free passage of nutrients, oxygen, and, indeed, smaller molecules, the cells are maintained within the capsules, and can produce and deliver therapeutic peptides to the brain. At the same time, cells transplanted into the brain are protected from the immunological graft -versus-host response. Upper right: The microcapsules are filled into a 1.5 x 1.5 cm-sized bag that is manually sutured from a polypropylene mesh with pores of up to 300 urn. A 5-cm tether for fixation of the implant to the skull surface is applied. CSF can pass through the pores providing the encapsulated cells with nutrients and oxygen. Lower left: The surgical hematoma is evacuated leaving the perihematomal area. Lower right: The mesh bag is implanted into the hematoma cavity, and it is removed 2 weeks after implantation by a second surgeiy. GLP, glucagon-like peptide; CSF, cerebrospinal fluid.

Article Snippet: While the cerebroventricular administration of trophic factors has influenced the pathology of neurodegenerative disorders, , the rapid clearance of CSF into the venous circulation has been recognized as a substantial limitation to the pharmakokinetics of this drug delivery route., The only reported clinical study investigating intraventricular, hollow fiber encapsulated cell biodelivery revealed only minimally increased CSF concentration of the delivered factor.

Techniques: Derivative Assay, Capsules